Danish drugmaker Novo Nordisk has said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the results fell short of the weight loss achieved with Eli Lilly’s rival drug Zepbound, according to analysts.
Patients on the once-weekly 7.2 mg dose of Novo’s drug for 72 weeks lowered their weight by 20.7% during the trial, compared with 17.5% for the 2.4 mg dose and 2.4% for the placebo, Reuters reports.
Results from a separate trial that were released in 2022 showed patients taking a high dose of Lilly’s Zepbound saw more than a 20% weight loss.
“The results give us greater confidence in long-term tirzepatide (Zepbound) market share,” according to analyst David Risinger.
Novo’s shares have been pressured since last year, when the company also suffered a setback after its experimental drug CagriSema showed lower-than-expected weight loss.
In December, Lilly said patients taking Zepbound lost 47% more weight than those who were given Wegovy in the first large, head-to-head trial of the highly in-demand rival medicines.
Detailed results from Novo’s trial testing the higher dose of Wegovy, which contains the active ingredient semaglutide, are expected to be presented at a scientific conference this year, the company said.
Results from a second late-stage trial testing a 7.2mg dose of Wegovy in adults with type 2 diabetes and obesity are expected within the next few months.
See more from MedicalBrief archives:
Ozempic, Wegovy rivals step up the pace in obesity drug gold rush
Cheaper obesity drugs in Indian and Chinese pipelines
Zepbound slashes diabetes risk by 94% – Eli Lilly